Texas MPN Workshop 2021 | Combining JAK, PIM kinase and CDK4/6 inhibition in MPNs
Raajit Rampal
• 20 Aug 2021
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale for the combined use of a JAK1/2 inhibitor, a PIM kinase inhibitor, and a CDK4/6 inhibitor for the treatment of myeloproliferative neoplasms (MPNs). Dr Rampal gives an overview of the findings of in vitro and murine studies which have explored this combination and reports that CDK4/6 inhibitors will be explored in clinical trials for myelofibrosis. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Raajit Rampal, MD, PhD, discloses associations with Abbvie, CTI, Sierra Oncology, Novartis, BMS/Celgene, Stemline, Disc Medicine, Blueprint, Kartos, Pharmaessentia, Incyte, Jazz Pharmaceuticals.
